Issue link: https://beckershealthcare.uberflip.com/i/984530
36 DEVICES & IMPLANTS CEO compensation for 8 spine, orthopedic device companies By Laura Dyrda C EOs of medical device company giants routinely make seven-figure salaries, with total compensation reaching even higher when bonuses and stock awards are included. Here are the 2016 salary and total compen- sation statistics for the CEOs of major device companies in the orthopedic and spine space. Alex Gorsky. Chairman and CEO of John- son & Johnson Salary: $1.6 million Total compensation: $21.2 million Omar Ishrak. Chairman and CEO of Medtronic* Salary: $1.6 million Total compensation: $15.4 million Kevin Lobo. Chairman, President and CEO of Stryker Salary: $1.1 million Total compensation: $12.8 million David Dvorak. Former President and CEO of Zimmer Biomet Salary: $1.1 million Total compensation: $10.6 million Mr. Dvorak was replaced by Daniel Florin in July 2017. Gregory Lucier. Chairman and CEO of NuVasive Salary: $800,000 Total compensation: $6.1 million Bradley Mason. President and CEO of Orthofix Salary: $705,576 Total compensation: $4.8 million Eric Major. President and CEO of K2M Salary: $525,000 Total compensation: $2.9 million David Paul. Chairman and CEO of Globus Medical Salary: $430,000 Total compensation: $1.7 million *Based on proxy statements filed for 2017 fiscal year n Smith & Nephew launch platform to engage patients, track surgical outcomes: 4 key points By Mackenzie Garrity I n partnership with Wellframe, Smith & Nephew launched a digital platform to allow orthopedic surgeons to track their patients' recovery progress and satisfaction. Here are four key points. 1. The platform uses HealthMeasure's Patient-Report- ed Outcomes Measurement Information System Com- puter-Adaptive Tests to collect data from patients. 2. Key tools include a personalized, daily checklist with education and reminders to patients to engage in be- haviors to aid in surgery preparation and recovery. 3. More than 25 percent of NHS post-operative paper PROs are not completed. This prevents accurate as- sessment of outcomes. 4. Smith & Nephew also launched research studies in the U.K. and U.S. at select hospitals to research the ac- curacy of clinical reporting and EHR use. n Zimmer Biomet vs. Amedica — Which company reported $7.82B in gross revenues? By Mackenzie Garrity Z immer Biomet and Amedica have seen steady growth over the past two years. Here is a compari- son of the companies' financial reports, according to The Leger Gazette. When comparing insider and institutional ownership, 86.5 percent of Zimmer Biomet's shares are owned by institutional investors while 5.6 percent of Amedica shares are owned by institutional investors. Zimmer Biomet also reported higher revenues and earnings compared to Amedica. In 2017, Zimmer Biomet reported $7.82 billion in revenues, and Amedica reported $15.23 mil- lion. The two companies also had stark differences in net in- come. Zimmer Biomet reported $1.81 billion while Amedica saw a $14.76 million loss in net income. Amedica's beta is at -1.36, suggesting its stock price is 236 percent less volatile. In comparison, Zimmer Biomet's beta is +1.13, meaning it is 13 percent more volatile. In all, Zimmer Biomet beat Amedica on 13 of 16 factors used to compare the companies. n